Cardiff Oncology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Cardiff Oncology, Inc. on June 26, 2025. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol CRDF.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
A total of 38,649,891 shares were represented at the meeting, constituting a quorum. The following matters were submitted to a vote:
- Proposal 1 (Election of Directors): All seven nominees were elected. Votes ranged from approximately 20.4 million to 21.2 million "For" votes, with zero "Against" votes for any nominee.
- Proposal 2 (Ratification of Auditors): The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ended December 31, 2025, was approved with 36,346,950 "For" votes.
- Proposal 3 (Equity Plan Amendment): Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of issuable shares to 12,150,000. This proposal received 16,897,666 "For" votes and 4,974,504 "Against" votes.
- Proposal 4 (Say-on-Pay): The advisory vote on executive compensation was approved with 18,881,817 "For" votes and 2,576,465 "Against" votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting results.
Key Facts for Investor Verification
- Verify the final share count and quorum status for the June 26, 2025 Annual Meeting.
- Confirm the successful ratification of BDO USA, P.C. as the auditor for the 2025 fiscal year.
- Note the significant "Against" vote count (approx. 5 million) on the Equity Incentive Plan amendment, indicating notable shareholder dissent on share dilution.
- Review the Definitive Proxy Statement filed on April 29, 2025, for detailed background on the proposals.